Cosmo Pharmaceuticals N.V Cash Flow-to-Debt Ratio
Cosmo Pharmaceuticals N.V cash flow-to-debt ratio. Cosmo Pharmaceuticals N.V (C43) has a Cash Flow-to-Debt Ratio of 0.02x as of June 2022, meaning its operating cash flow of €6.28 Million could theoretically repay 0% of its total liabilities (€296.03 Million) in one year. Check C43 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Cosmo Pharmaceuticals N.V (2016–2025)
Cash flow-to-debt ratio of Cosmo Pharmaceuticals N.V from 2016 to 2025. Historical debt coverage capacity for Cosmo Pharmaceuticals N.V across 10 annual periods. Check total reinvestment intensity of Cosmo Pharmaceuticals N.V to assess the company's total reinvestment commitment from operating cash flow.
Cosmo Pharmaceuticals N.V Cash Flow-to-Debt Ratio by Year (2016–2025)
Cosmo Pharmaceuticals N.V cash flow-to-debt ratio by year from 2016 to 2025. Year-by-year debt coverage analysis for Cosmo Pharmaceuticals N.V. For the full cash flow conversion analysis, see C43 operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.10x | €-12.48 Million | €123.46 Million | ▼ -108.8% |
| 2024 | 1.15x | €162.41 Million | €141.68 Million | ▲ +317.4% |
| 2023 | 0.27x | €33.62 Million | €122.42 Million | ▲ +144.5% |
| 2022 | 0.11x | €33.23 Million | €295.80 Million | ▲ +160.9% |
| 2021 | 0.04x | €12.61 Million | €292.88 Million | ▼ -35.0% |
| 2020 | 0.07x | €12.98 Million | €196.04 Million | ▲ +167.3% |
| 2019 | -0.10x | €-18.85 Million | €191.43 Million | ▼ -75.2% |
| 2018 | -0.06x | €-10.16 Million | €180.83 Million | ▲ +83.4% |
| 2017 | -0.34x | €-9.43 Million | €27.86 Million | ▼ -143.6% |
| 2016 | 0.78x | €21.69 Million | €27.92 Million | — |